AU2012252380B2 - Polymorph of Linagliptin benzoate - Google Patents

Polymorph of Linagliptin benzoate Download PDF

Info

Publication number
AU2012252380B2
AU2012252380B2 AU2012252380A AU2012252380A AU2012252380B2 AU 2012252380 B2 AU2012252380 B2 AU 2012252380B2 AU 2012252380 A AU2012252380 A AU 2012252380A AU 2012252380 A AU2012252380 A AU 2012252380A AU 2012252380 B2 AU2012252380 B2 AU 2012252380B2
Authority
AU
Australia
Prior art keywords
linagliptin benzoate
linagliptin
crystalline form
present
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012252380A
Other languages
English (en)
Other versions
AU2012252380A1 (en
Inventor
Andreas Hotter
Arthur Pichler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of AU2012252380A1 publication Critical patent/AU2012252380A1/en
Application granted granted Critical
Publication of AU2012252380B2 publication Critical patent/AU2012252380B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2012252380A 2011-05-10 2012-05-09 Polymorph of Linagliptin benzoate Ceased AU2012252380B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11165597.3 2011-05-10
EP11165597 2011-05-10
PCT/EP2012/058556 WO2012152837A1 (en) 2011-05-10 2012-05-09 Polymorph of linagliptin benzoate

Publications (2)

Publication Number Publication Date
AU2012252380A1 AU2012252380A1 (en) 2013-11-28
AU2012252380B2 true AU2012252380B2 (en) 2016-09-08

Family

ID=44227877

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012252380A Ceased AU2012252380B2 (en) 2011-05-10 2012-05-09 Polymorph of Linagliptin benzoate

Country Status (9)

Country Link
US (1) US8785455B2 (enExample)
EP (1) EP2707368B1 (enExample)
JP (1) JP6028016B2 (enExample)
CN (1) CN103596954B (enExample)
AU (1) AU2012252380B2 (enExample)
CA (1) CA2835332C (enExample)
EA (1) EA023330B1 (enExample)
SI (1) SI2707368T1 (enExample)
WO (1) WO2012152837A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
NZ573360A (en) 2006-05-04 2012-08-31 Boehringer Ingelheim Int Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
CA2782179C (en) 2009-11-27 2020-06-23 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
PT2566469T (pt) 2010-05-05 2023-01-10 Boehringer Ingelheim Int Terapia de combinação
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
PL3517539T3 (pl) 2011-07-15 2023-04-24 Boehringer Ingelheim International Gmbh Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
CN105712995B (zh) * 2014-12-05 2017-11-03 浙江京新药业股份有限公司 一种利格列汀的纯化方法
KR102442536B1 (ko) * 2015-09-17 2022-09-13 한미정밀화학주식회사 리나글립틴 결정형 및 이의 제조방법
JP6839708B2 (ja) 2015-10-09 2021-03-10 ヘクサル・アクチェンゲゼルシャフトＨｅｘａｌ ＡＧ ８−［（３ｒ）−３−アミノ−１−ピペリジニル］−７−（２−ブチン−１−イル）−３，７−ジヒドロ−３−メチル−１−［４−メチル−２−キナゾリニル）メチル］−１ｈ−プリン−２，６−ジオンまたは薬学上許容できるその塩を含有する医薬組成物
MX390363B (es) 2016-06-10 2025-03-20 Boehringer Ingelheim Int Combinacion de linagliptina y metformina
CN106543180B (zh) * 2016-10-28 2018-03-30 南京正大天晴制药有限公司 苯甲酸利格列汀晶型及其制备方法
EP3842575A4 (en) * 2018-08-21 2022-06-01 Towa Pharmaceutical Co., Ltd. SPECIFIC SHAPED CRYSTAL OF A COMPOUND AND METHOD OF PRODUCTION THEREOF

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010072776A1 (en) * 2008-12-23 2010-07-01 Boehringer Ingelheim International Gmbh Salt forms of organic compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2070539A1 (de) 2002-08-21 2009-06-17 Boehringer Ingelheim Pharma GmbH & Co. KG 8-[3-Amino-Piperidin-1-YL]-Xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
NZ573360A (en) 2006-05-04 2012-08-31 Boehringer Ingelheim Int Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
CL2008002427A1 (es) * 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
US8835472B2 (en) * 2010-09-02 2014-09-16 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010072776A1 (en) * 2008-12-23 2010-07-01 Boehringer Ingelheim International Gmbh Salt forms of organic compound

Also Published As

Publication number Publication date
CA2835332C (en) 2019-03-26
US8785455B2 (en) 2014-07-22
WO2012152837A1 (en) 2012-11-15
CN103596954B (zh) 2016-10-26
US20140121225A1 (en) 2014-05-01
JP6028016B2 (ja) 2016-11-16
CN103596954A (zh) 2014-02-19
SI2707368T1 (sl) 2016-04-29
AU2012252380A1 (en) 2013-11-28
EP2707368A1 (en) 2014-03-19
EA201301240A1 (ru) 2014-04-30
EP2707368B1 (en) 2016-02-03
EA023330B1 (ru) 2016-05-31
CA2835332A1 (en) 2012-11-15
JP2014513143A (ja) 2014-05-29

Similar Documents

Publication Publication Date Title
AU2012252380B2 (en) Polymorph of Linagliptin benzoate
AU2011307608B8 (en) Crystalline naloxol-PEG conjugate
TW200944508A (en) Novel solid forms of bendamustine hydrochloride
CN104379582A (zh) 包含达沙替尼和所选择的共晶体形成剂的多组分晶体
JP7075884B2 (ja) アビバクタムナトリウムのｃ形
WO2020115212A1 (en) Crystalline phosphate salt of selective jak1 inhibitor upadacitinib
CZ2016276A3 (cs) Pevné formy volné báze ibrutinibu
JP2024522603A (ja) （３ｒ）－ｎ－［２－シアノ－４－フルオロ－３－（３－メチル－４－オキソ－キナゾリン－６－イル）オキシ－フェニル］－３－フルオロ－ピロリジン－１－スルホンアミドの新規固形物
WO2020182978A1 (en) Crystalline salt of a 5-ht2a receptor antagonist
JP7303821B2 (ja) ピリミジニルアミノ－ピラゾール化合物の多形体及び固体形態、ならびに製造方法
KR100878698B1 (ko) 결정형의 베포타스틴 금속염 수화물, 이의 제조방법 및이를 포함하는 약학 조성물
US8361971B2 (en) Tablet formulation of ezatiostat
WO2014009970A2 (en) Linagliptin solid dispersion
JP2012131786A (ja) 活性医薬成分の結晶形態
WO2022162107A1 (en) Crystalline form of risdiplam
EP3181565A1 (en) Crystalline omarigliptin salts
EP4126237B1 (en) Dimaleate form of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea
KR101307712B1 (ko) 결정형의 베포타스틴 금속염 수화물, 이의 제조방법 및 이를 포함하는 약학 조성물
WO2019086509A1 (en) Crystalline salt of a tricyclic poly(adp-ribose) polymerase inhibitor
US9381199B2 (en) Linagliptin solid dispersion

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired